Zydus Lifesciences: Zylidac Bio and Prolific Machines Partner to Scale Prolific's Next-Generation Biologics Manufacturing…
Zydus Lifesciences (ZYDUSLIFE) filed a disclosure titled "Zylidac Bio and Prolific Machines Partner to Scale Prolific's Next-Generation Biologics Manufacturing Platform to GMP Production". The company is valued at about ₹1.11 lakh crore.
What happened
Zydus Lifesciences (ZYDUSLIFE) filed a disclosure with the exchanges on 21 October 2026 at 06:27 PM titled "Zylidac Bio and Prolific Machines Partner to Scale Prolific's Next-Generation Biologics Manufacturing Platform to GMP Production".
Company snapshot
Zydus Lifesciences is a large-cap company in the Healthcare sector, with a market value of about ₹1.11 lakh crore.
The stock last traded at ₹1,117.3, against a 52-week range of ₹835.5–₹1,232.1 (9.3% below the high).
Before this filing the shares had moved −1.9% over the month and −2.5% over three months. Average daily turnover over the last 20 sessions was about ₹183 crore.
Promoters held 75.01% at the end of Q1 FY27. Foreign institutions owned 6.88% and domestic institutions 11.27%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 6,574 | 1,466.8 | 14.58 |
| Q2 FY26 | 6,123 | 1,258.6 | 12.51 |
| Q3 FY26 | 6,865 | 1,042.1 | 10.36 |
| Q4 FY26 | 7,587 | 1,272.5 | 12.65 |
| Q1 FY27 | 8,017 | 939.8 | 9.35 |
What history shows
This is not the company's first corporate update disclosure: BCEIE has at least 12 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 0.8% on average the next trading day and was down 0.4% on average after five days (10 filings with price data).
Across 6 similar disclosures by other Healthcare companies, shares moved −1.0% on average the next day and −4.2% over five days; 67% of them rose the next day.
Market-wide, 273 corporate update filings with an impact score of 50 or more saw an average next-day move of −0.2%, with 41% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 13 Oct 2026 | USFDA Inspection | +0.7% | — |
| 12 Oct 2026 | Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3… | −0.9% | — |
| 5 Oct 2026 | Zydus, MSN partner to Launch First Generic of Adempas (Riociguat… | +1.2% | −0.6% |
| 1 Oct 2026 | Corporate update | +1.2% | −1.0% |
| 1 Oct 2026 | Extension of date of closing | +1.2% | −1.0% |
What to watch
- 4 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Zydus Lifesciences Gets USFDA Approval for Hormone Patch
- ZYDUSLIFE Share Price Today - Zydus Life Science on NSE/BSE
- Zydus Lifesciences' USFDA inspection at Ahmedabad plant concludes with 5 observations
- Zydus Lifesciences Ltd Share/Stock Price Live Today | The HinduBusinessLine
- Mankind Pharma, Zydus Lifesciences among top losers, fall up to 3% after Supreme Court asks Centre to...
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.